The n e w e ng l a n d j o u r na l of m e dic i n e Original Article Lecanemab in Early Alzheimer’s Disease C.H. van Dyck, C.J. Swanson, P. Aisen, R.J. Bateman, C. Chen, M. Gee, M. Kanekiyo, D. Li, L. Reyderman, S. Cohen, L. Froelich, S. Katayama, M....
More
The n e w e ng l a n d j o u r na l of m e dic i n e Original Article Lecanemab in Early Alzheimer’s Disease C.H. van Dyck, C.J. Swanson, P. Aisen, R.J. Bateman, C. Chen, M. Gee, M. Kanekiyo, D. Li, L. Reyderman, S. Cohen, L. Froelich, S. Katayama, M. Sabbagh, B. Vellas, D. Watson, S. Dhadda, M. Irizarry, L.D. Kramer, and T. Iwatsubo A BS T R AC T BACKGROUND The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may ini- The authors’ full names, academic de- tiate or potentiate pathologic processes in Alzheimer’s disease. Lecanemab, a human- grees, and affiliations are listed in the Ap- pendix. Dr. van Dyck can be contacted at ized IgG1 monoclonal antibody that binds with high affinity to Aβ soluble proto- christopher.vandyck@yale.edu or at the fibrils, is being tested in persons with early Alzheimer’s disease. Alzheimer’s Disease Research Unit, Divi- sion of Aging and Geriatric Psychiatry, METHODS Yale School of Medicine, 1 Church St., We conducted an 18-month, multi
Less
